News & Perspective

(CIDRAP News) – The National Institutes of Health (NIH) yesterday announced it has awarded contracts, which could total $150 million over 5 years, to four companies to develop broad-spectrum therapies that could help the nation respond to a bioterror attack or other public health emergency.

(CIDRAP News) – Emergent BioSolutions Inc. recently announced that it won a federal contract worth $24.3 million to develop a monoclonal antibody treatment to block the effects of anthrax toxin.

(CIDRAP News) – The US government recently awarded contracts totaling about $34 million to two companies for development of drugs to treat pneumonic plague, tularemia, and anthrax, three of the diseases terrorists are deemed most likely to try to exploit.

(CIDRAP News) – A new analysis of research into the 1918 influenza pandemic, undertaken to determine whether historical accounts can illuminate planning for possible future pandemics, reveals a surprising number of enduring mysteries.

(CIDRAP News) – Two research reports on plague were recently released, one describing the mechanism that the plague bacterium uses to evade the body's immune system and the other describing a potential vaccine that was tested successfully in mice.

Editor's note: This story was revised shortly after publication to reflect corrections issued by the National Institute of Allergy and Infectious Diseases on May 10. The corrections pertain to the total monetary amount of the grants and to the project descriptions for XOMA (US) LLC and DVC Dynport LLC.

(CIDRAP News) – Federal health officials yesterday released a 37-page report that they say demonstrates "tremendous progress" in developing countermeasures for bioterrorism through federally funded research since early 2002.

(CIDRAP News) – The US Department of Health and Human Services yesterday announced $350 million in grants for eight regional centers to lead and coordinate research on defenses against bioterrorism and emerging infectious diseases.

(CIDRAP News) – The National Institute of Allergy and Infectious Diseases (NIAID) has released a 68-page report on its plan for expanding research on "Category A" bioterrorism agents: anthrax, smallpox, plague, tularemia, viral hemorrhagic fevers, and botulism.